The University of Cincinnati Cancer Center announced a major breakthrough for Ohio patients and families battling pancreatic cancer. The Food and Drug Administration approved daraxonrasib on Wednesday, marking the first new treatment for the most common form of pancreatic cancer in years.
Local researchers at the forefront
Scientists and clinicians at the University of Cincinnati have been conducting clinical trials with daraxonrasib for multiple years. Dr. Davendra Sohal, a lead investigator, said the drug’s impact is “unheard of,” noting that patients are living more than twice as long and avoiding the harsh side effects of traditional chemotherapy.
How the drug works
Daraxonrasib targets a specific mutated protein that fuels tumor growth in many pancreatic cancer cases. By blocking this protein, the medication slows disease progression, giving patients more time with a better quality of life. The FDA’s approval means doctors can begin prescribing the therapy as early as Friday.
Impact on Ohio families
Pancreatic cancer remains one of the deadliest cancers in the United States. The American Cancer Society estimates about 67,000 new cases nationwide this year, with more than 52,000 deaths. Ohio families, already grappling with the disease’s late‑stage diagnosis, now have a promising new option close to home.
Local hospitals and oncology clinics are preparing to integrate daraxonrasib into treatment protocols. While the exact cost of the drug has not yet been disclosed, the University’s partnership with insurers aims to make the medication accessible to as many patients as possible.
What’s next for research
The Cancer Center plans to continue studying daraxonrasib’s long‑term effects and explore combinations with other therapies. Researchers hope the success of this drug will spur further investment in Ohio’s biomedical research sector, creating jobs and reinforcing the state’s reputation for medical innovation.
For patients and families seeking more information, the University of Cincinnati Cancer Center has set up a dedicated hotline and online resources to explain eligibility, treatment timelines, and insurance coverage options.
Original reporting: WLWT Cincinnati — read the source article.
